Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 29 2024 - 6:05AM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced that members of its senior management team will
participate at two upcoming investor conferences. Details for the
presentations are as follows.
TD Cowen 44th Annual Healthcare Conference Panel
Discussion: Gynecological Cancers Date: Tuesday, March 5, 2024
Time: 10:30 a.m. Eastern Time Location: Boston, MA
Bloom Burton 2024 Healthcare Investor Conference Company
Overview Date: Tuesday, April 16, 2024 Time: 3:30 p.m. Eastern Time
Location: Toronto, ON
A live webcast of the TD Cowen corporate panel discussion and
Bloom Burton company overview can be accessed in the Investor
section of the Company’s website at
https://ir.reparerx.com/news-and-events/events. A replay of the
webcast will be archived on the Company’s website for at least 30
days.
About Repare Therapeutics, Inc. Repare Therapeutics is a
leading clinical-stage precision oncology company enabled by its
proprietary synthetic lethality approach to the discovery and
development of novel therapeutics. The Company utilizes its
genome-wide, CRISPR-enabled SNIPRx® platform to systematically
discover and develop highly targeted cancer therapies focused on
genomic instability, including DNA damage repair. The Company’s
pipeline includes lunresertib (also known as RP-6306), a PKMYT1
inhibitor currently in Phase 1/2 clinical development; camonsertib
(also known as RP-3500), a potential leading ATR inhibitor
currently in Phase 1/2 clinical development; RP-1664, a Phase 1
PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor
program; as well as additional, undisclosed preclinical programs.
For more information, please visit reparerx.com and follow
@Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229323391/en/
Repare Contact: Robin Garner Vice President and Head of
Investor Relations Repare Therapeutics Inc.
investor@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Jan 2024 to Jan 2025